8th Int Congress on Drug Therapy in HIV
Infection
|
-
A
pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID)
enfuvirtide (ENF)
D Wright, A Rodriguez, E Godofsky, et al
Abstract-
Injection site reactions (ISR) and success of HAART influence continued use of
enfuvirtide (T20)
M Vogel, E Wolf, K Ummard, et al
Abstract-
Evaluation of the local tolerance and quality of life in 60 HIV-1 infected
patients treated with an
ARV
regimen containing enfuvirtide: SURCOUF cohort
C Allavena, T Prazuck, G Le Moal, et al
Abstract-
Prospective study assessing injection site reactions, quality of life and
enfuvirtide administration
preference using Biojector versus needles
M Loutfy, M Harris, J Raboud, et al
Abstract-
Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent
active mycobacterial
infection: a pilot experienceInter-country variation in physician perspectives of enfuvirtide (ENF)
prescribing
R Horne, V Cooper, G Gellaitry
Abstract-
Switching a toxicity-causing antiretroviral (ARV) to enfuvirtide (ENF) in
patients with treatment-
limiting toxicities
M Stoll, M Muller, S Staszewski, et al
Abstract
-
Mitochondrial DNA (mtDNA) content in enfuvirtide-treated healthy volunteers
G Garrabou, S Lopez, V Rodriguez, et al
Abstract
XVI International AIDS Conference
|
-
Patients’ and physicians’ attitudes and perceptions towards oral
versus subcutaneous
Highly Active antiretroviral Therapy (HAART)
C Rodríguez Fumaz, H Knobel Freud, A Segador Gómez, et
al
Abstract
-
Long-term efficacy of enfurvitide - the RADATA-Fuzeon
cohort
C Hoffmann , T Lorenzen , K Arasteh, et al
Abstract
-
Discontinuation of enfuvirtide after long-term administration in
HIV-1-infected patients –
the Swiss HIV cohort study (SHCS)
L Elzi, G Kaufmann, R Weber, et al
Abstract
-
Combination of TMC114/ritonavir and TMC125 in patients
with multidrug resistant HIV
J Montaner , M. Harris 1, G. Larsen , et al
Abstract
-
TMC114/r in treatment-experienced HIV patients in power 3: 24-week
efficacy and safety analysis
JM Molina, C Cohen, C Katlama, et al
Abstract
-
Design of a novel peptidic HIV-1 fusion inhibitor
against drug-resistant viruses
J Chen Y He , M. Dong
Abstract
-
Analysis of cost of full virologic suppression for
treatment-experienced, HIV-infected patients
A Hill, C Smith
Abstract
-
Absence of TMC114 exposure-efficacy and exposure-safety relationships
in power 3
V Sekar, S De Meyer, T Vangeneugden,
Abstract
-
Injectable therapy in HIV: the role of physician and
patient attitudes
R Horne, V Cooper, C Tsoukas
Abstract
-
Prevalence of GP41 resistance-associated mutations and polymorphism in
naive patients:
analysis of 1703 HIV-1 sequences over a 20 years period
AAN Al Hawajr, C Alloui, E Gault, et al
Abstract
-
Success of rescue therapy with TMC114 in HIV-infected patients who
failed multiple
ritonavir-boosted protease inhibitor-based regimens
E Poveda, F Blanco, P García-Gasco,
et al
Abstract-
Positive patient adherence and satisfaction using a novel nursing
support program as part of
enfuvirtide therapy
E. Sweeney, N. Johnson, M. DeSpirito, B. Greer
Abstract-
Does enfuvirtide perception change when
patients used it?
N. Terrail, S. Guessant, V. Dubois, et al
Abstract
-
Discontinuation of enfuvirtide after long-term administration in
HIV-1-infected patients – the Swiss
HIV cohort study (SHCS)
L. Elzi, G. Kaufmann, R. Weber, ., et al
Abstract
-
CD4 increases in patients with ongoing viral replication while
receiving enfuvirtide are associated
with V38 and other mutations in gp41
T. Melby, M. DeSpirito, R. Demasi, G., et al
Abstract
-
Quality of life (Qol) and tolerability after administration of
enfuvirtide (ENF) with a 31-Gauge,
thin-walled, 8mm needle (QUALITE study)
P. Shalit, A. True, J. Thommes, et al
Abstract
-
Currently marketed nucleos(t)ides provide only marginal additional
viral load (VL) suppression to
regimens including enfuvirtide (ENF) and boosted PIs (PI/r) in triple
class experienced patients
(TEPs)
R. DeMasi, J. Thommes, N. Graham, et al
Abstract
-
Evolution of genotyping and phenotyping resistance to enfuvirtide in
HIV-infected patients with
persistent viraemia, during and after treatment
M.-A. Trabaud, L. Cotte, J.L. Labernardière, et al
Abstract
-
A nonrandomized large prospective evaluation of alternative injection
devices (Biojector® 2000
(B2000), standard needles/syringes, or insulin needles/syringes) for
enfuvirtide (ENF) in a national
community-based specialty pharmacy
S. Tschida, A. Zappa, M. Godwin, et al
Abstract
-
The mechanism of enfuvirtide resistance and structural insights into
the corresponding fitness
deficits in response to the N43D resistance mutation
X. Bai, J. Seedorff, K. Wilson, et al
Abstract
|
 |
Enfuvirtide Main Page
